Illumina Inc (ILMN) 192.58 $ILMN
IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 72.87 (+0.51), AAP: 146.96 (+1.25), AKRX: 44.55 (+0.91), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), CDW: 30.84 (+0.71), CELG: 107.09 (+0.15), BIDU: 238.77 (+1.76), GILD: 112.00 (-2.22), JAZZ: 168.84 (-0.98), FLT: 150.56 (+8.01), FL: 56.01 (+0.16), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:30PM CDT
Following the earnings release, shares of Affymetrix Inc. (AFFX) climbed 2.3% to close at $8.30 in the last session.
BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMAG: 33.01 (-0.95), AFFX: 9.01 (+0.71)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), ILMN: 192.58 (-0.84)
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 7:51AM CDT
Novo Nordisk A/S (NVO) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), NVO: 45.18 (-1.03), ILMN: 192.58 (-0.84)
Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 321.08 (+0.08), HSKA: 13.99 (+0.42), ILMN: 192.58 (-0.84), QGEN: 23.46 (-0.23)
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:39AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), CARA: 9.01 (-0.18), ILMN: 192.58 (-0.84)
Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:25AM CDT
Oncolytics Biotech (ONCY) was a big mover last session, with shares surging almost 26% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ONCY: 1.00 (+0.18), ILMN: 192.58 (-0.84)
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ANIP: 33.96 (+0.91), ILMN: 192.58 (-0.84)
HTG Announces Completion of IVD Development and Supply Agreement With Illumina
Marketwired - Thu Oct 30, 6:03AM CDT
HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ: ILMN), under which HTG will have the right to develop certain in-vitro diagnostic (IVD) test kits that utilize Illumina sequencing technology.
ILMN: 192.58 (-0.84)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60)
The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), MDCO: 25.32 (-0.34), ILMN: 192.58 (-0.84)
Chipotle And Apple Suppliers Rise Among 5 Young Guns
at Investor's Business Daily - Wed Oct 29, 7:02AM CDT
Youth has its advantages. Young companies often come out of the gate strong, and strong growth keeps them looking young. Today's Young Guns Screen of the Day features hot picks that have gone public in the last 15 years. In particular, the stocks...
SNCR: 51.67 (-0.66), FB: 74.99 (+0.88), CMG: 638.00 (-1.68), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)
Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Oct 28, 10:58PM CDT
Investors are not loving the latest earnings report from Gilead (GILD) pushing the stock lower by 4 percent after hours.
BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), ILMN: 192.58 (-0.84)
Novavax (NVAX) in Focus: Stock Rises 13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:44AM CDT
Novavax (NVAX) was a big mover last session, as the company saw its shares surge over 13% on the day.
MDVN: 105.70 (+2.96), ONCY: 1.00 (+0.18), NVAX: 5.60 (-0.03), ILMN: 192.58 (-0.84)
Can Illumina (ILMN) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:41AM CDT
Illumina is well-positioned for future earnings growth and could be a strong growth stock contender
ILMN: 192.58 (-0.84)
Global Whole Exome Sequencing Market 2018 - Analysis of the $800+ Million Industry
M2 - Tue Oct 28, 6:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3kwgp3/whole_exome) has announced the addition of the "Whole Exome Sequencing Market by Product, by Services, by Technology, by Application - Global Forecast to 2018" report to their offering. The global whole exome sequencing market is expected to reach $884.1 Million by 2018 Advances in DNA sequencing have transformed genomics and paved the way for whole exome sequencing in research. Whole exome sequencing is cost-efficient and quick, as compared to whole-genome sequencing. Sequencing the exome is also considered more effective, as exons possess 85% of disease traits. Thus, WES systems, kits, and services have seen increased adoption by researchers as they not only simplify work but also save time. Technological advancements in sequencing systems, global alliances amongst leading research institutes to boost drug discovery, and an increase in life science and R&D expenditure are the key factors that are expected to drive the growth of this market. Primary factors that are restraining the growth of this market include high instrument costs, the need for skilled professionals, and high reliance on grants and funds. The major factors driving the growth of this market include its low cost and high speed, increase in applications areas for exome sequencing technologies, global alliances amongst leading research institutes to boost drug discovery, and the entry of new players in the whole-exome sequencing market. However, the high cost of instruments, the need for skilled professionals and high reliability on grants are hindering the market's growth. The services segment has the largest share of the global whole exome sequencing market, since it has a variety of applications in all areas, including diagnostics, drug discovery and development, personalized medicine, and agriculture and animal research. Diagnostics emerged as the largest whole exome sequencing application, primarily because of an increase in the usage of exome sequencing technologies in cancer and rare disease research. Scope of the Report Product - Systems - Kits (Library Preparation, Target Enrichment) Services - Sequencing Technology - Sequencing - Synthesis Application - Cancer - Monogenic disorders Companies Mentioned - Agilent Technologies, Inc. - Ambry Genetics - Beijing Genomics Institute (Bgi) - Eurofins Genomics, Inc. - Genewiz, Inc. - Illumina, Inc. - Knome, Inc. - Macrogen, Inc. - Roche Nimblegen, Inc. - Sengenics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/3k...hole_exome
A: 55.28 (+0.96), ILMN: 192.58 (-0.84)
Four Biotechs Lead Health Care Stocks In Big Cap 20
at Investor's Business Daily - Mon Oct 27, 6:00PM CDT
Medical stocks are flexing their muscles in the latest Big Cap 20 list, as they've more than doubled in number from the prior week. Even though a few medical sectors make the cut, biotechs are well represented. The group earned the top ranking in...
VRX: 133.04 (+1.53), ALXN: 191.36 (-1.57), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60), REGN: 393.72 (+0.92), CELG: 107.09 (+0.15)
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.16% Gain
Comtex SmarTrend(R) - Mon Oct 27, 4:19PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $187.51 to a high of $192.49. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $190.86 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 192.58 (-0.84)
Illumina Rises 1.16% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 27, 4:18PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $187.51 to a high of $192.49. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $190.86 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 192.58 (-0.84)
IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 72.87 (+0.51), AAP: 146.96 (+1.25), AKRX: 44.55 (+0.91), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), CDW: 30.84 (+0.71), CELG: 107.09 (+0.15), BIDU: 238.77 (+1.76), GILD: 112.00 (-2.22), JAZZ: 168.84 (-0.98), FLT: 150.56 (+8.01), FL: 56.01 (+0.16), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:30PM CDT
Following the earnings release, shares of Affymetrix Inc. (AFFX) climbed 2.3% to close at $8.30 in the last session.
BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMAG: 33.01 (-0.95), AFFX: 9.01 (+0.71)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), ILMN: 192.58 (-0.84)
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 7:51AM CDT
Novo Nordisk A/S (NVO) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), NVO: 45.18 (-1.03), ILMN: 192.58 (-0.84)
Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 321.08 (+0.08), HSKA: 13.99 (+0.42), ILMN: 192.58 (-0.84), QGEN: 23.46 (-0.23)
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:39AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), CARA: 9.01 (-0.18), ILMN: 192.58 (-0.84)
Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:25AM CDT
Oncolytics Biotech (ONCY) was a big mover last session, with shares surging almost 26% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ONCY: 1.00 (+0.18), ILMN: 192.58 (-0.84)
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ANIP: 33.96 (+0.91), ILMN: 192.58 (-0.84)
HTG Announces Completion of IVD Development and Supply Agreement With Illumina
Marketwired - Thu Oct 30, 6:03AM CDT
HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ: ILMN), under which HTG will have the right to develop certain in-vitro diagnostic (IVD) test kits that utilize Illumina sequencing technology.
ILMN: 192.58 (-0.84)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60)
The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), MDCO: 25.32 (-0.34), ILMN: 192.58 (-0.84)
Chipotle And Apple Suppliers Rise Among 5 Young Guns
at Investor's Business Daily - Wed Oct 29, 7:02AM CDT
Youth has its advantages. Young companies often come out of the gate strong, and strong growth keeps them looking young. Today's Young Guns Screen of the Day features hot picks that have gone public in the last 15 years. In particular, the stocks...
SNCR: 51.67 (-0.66), FB: 74.99 (+0.88), CMG: 638.00 (-1.68), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)
Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Oct 28, 10:58PM CDT
Investors are not loving the latest earnings report from Gilead (GILD) pushing the stock lower by 4 percent after hours.
BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), ILMN: 192.58 (-0.84)
Novavax (NVAX) in Focus: Stock Rises 13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:44AM CDT
Novavax (NVAX) was a big mover last session, as the company saw its shares surge over 13% on the day.
MDVN: 105.70 (+2.96), ONCY: 1.00 (+0.18), NVAX: 5.60 (-0.03), ILMN: 192.58 (-0.84)
Can Illumina (ILMN) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:41AM CDT
Illumina is well-positioned for future earnings growth and could be a strong growth stock contender
ILMN: 192.58 (-0.84)
Global Whole Exome Sequencing Market 2018 - Analysis of the $800+ Million Industry
M2 - Tue Oct 28, 6:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3kwgp3/whole_exome) has announced the addition of the "Whole Exome Sequencing Market by Product, by Services, by Technology, by Application - Global Forecast to 2018" report to their offering. The global whole exome sequencing market is expected to reach $884.1 Million by 2018 Advances in DNA sequencing have transformed genomics and paved the way for whole exome sequencing in research. Whole exome sequencing is cost-efficient and quick, as compared to whole-genome sequencing. Sequencing the exome is also considered more effective, as exons possess 85% of disease traits. Thus, WES systems, kits, and services have seen increased adoption by researchers as they not only simplify work but also save time. Technological advancements in sequencing systems, global alliances amongst leading research institutes to boost drug discovery, and an increase in life science and R&D expenditure are the key factors that are expected to drive the growth of this market. Primary factors that are restraining the growth of this market include high instrument costs, the need for skilled professionals, and high reliance on grants and funds. The major factors driving the growth of this market include its low cost and high speed, increase in applications areas for exome sequencing technologies, global alliances amongst leading research institutes to boost drug discovery, and the entry of new players in the whole-exome sequencing market. However, the high cost of instruments, the need for skilled professionals and high reliability on grants are hindering the market's growth. The services segment has the largest share of the global whole exome sequencing market, since it has a variety of applications in all areas, including diagnostics, drug discovery and development, personalized medicine, and agriculture and animal research. Diagnostics emerged as the largest whole exome sequencing application, primarily because of an increase in the usage of exome sequencing technologies in cancer and rare disease research. Scope of the Report Product - Systems - Kits (Library Preparation, Target Enrichment) Services - Sequencing Technology - Sequencing - Synthesis Application - Cancer - Monogenic disorders Companies Mentioned - Agilent Technologies, Inc. - Ambry Genetics - Beijing Genomics Institute (Bgi) - Eurofins Genomics, Inc. - Genewiz, Inc. - Illumina, Inc. - Knome, Inc. - Macrogen, Inc. - Roche Nimblegen, Inc. - Sengenics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/3k...hole_exome
A: 55.28 (+0.96), ILMN: 192.58 (-0.84)
Four Biotechs Lead Health Care Stocks In Big Cap 20
at Investor's Business Daily - Mon Oct 27, 6:00PM CDT
Medical stocks are flexing their muscles in the latest Big Cap 20 list, as they've more than doubled in number from the prior week. Even though a few medical sectors make the cut, biotechs are well represented. The group earned the top ranking in...
VRX: 133.04 (+1.53), ALXN: 191.36 (-1.57), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60), REGN: 393.72 (+0.92), CELG: 107.09 (+0.15)
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.16% Gain
Comtex SmarTrend(R) - Mon Oct 27, 4:19PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $187.51 to a high of $192.49. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $190.86 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 192.58 (-0.84)
Illumina Rises 1.16% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 27, 4:18PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $187.51 to a high of $192.49. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $190.86 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 192.58 (-0.84)
